Bedrijfsoverzicht
Abeona Therapeutics Inc. operates as a commercial-stage biopharmaceutical company dedicated to developing gene and cell therapies for life-threatening diseases within the United States, with its primary focus on ZEVASKYN, an autologous, cell-based gene therapy designed to treat patients suffering from recessive dystrophic epidermolysis bullosa. The enterprise functions within the Healthcare sector and specifically the Biotechnology industry, a classification that defines its reliance on intensive research and development to create proprietary biological treatments rather than manufacturing standard consumer goods. The company maintains a market capitalization of $280.11M and employs a workforce of 226 individuals to support its operational and development goals. These financial figures indicate that Abeona is a mid-cap entity with a relatively small revenue base of $5.82M, suggesting it is still in a growth phase where capital allocation prioritizes pipeline expansion over maximizing current profitability, which is typical for early-to-mid stage biotechnology firms seeking regulatory approval for specialized therapies.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $5.82M alongside a net income of $71.18M and an EBITDA of -$86,899,000. The substantial disparity between the reported net income and the negative EBITDA reveals a highly leveraged cost structure where non-operating income, likely from equity valuation adjustments or other financial engineering common in pre-profit biotech firms, is artificially inflating the bottom line despite significant operational losses. Free cash flow stands at -$55,598,500, indicating that the company is burning cash at a rapid pace, which necessitates continuous external financing or the utilization of existing cash reserves to sustain operations and fund clinical trials. The gross margin is recorded at 0.0%, while the operating margin is a negative 422.7% and the profit margin is an anomalous 1223.1%; the negative gross and operating margins confirm the lack of profitability from core operations, whereas the inflated profit margin is a mathematical artifact of the negative EBITDA being offset by the massive non-operating net income. On the balance sheet, Abeona holds $191.40M in cash against $24.97M in debt, resulting in a debt-to-equity ratio of 15.68, which suggests a highly leveraged position relative to equity but provides a substantial cash buffer given the absolute dollar amounts held. The current ratio is 6.93, a metric that indicates strong short-term liquidity and an ability to cover short-term obligations with current assets, although the quality of those assets may be tied up in research and development cycles. Return on Equity is 70.0% and Return on Assets is -34.0%; the high positive ROE is driven by the leverage and non-operating gains, while the negative ROA accurately reflects that the assets employed in the business are generating losses from operations.
Waarderingsbeoordeling
The trailing P/E ratio is 4.86, while the forward P/E is projected at 20.46, implying that the market expects a significant shift in earnings trajectory where future earnings are anticipated to be much lower or more volatile than the current period due to the inclusion of expected losses in the forward calculation. The price-to-book ratio stands at 1.70, indicating that the market values the company at a 70% premium over its book value, which reflects the intangible value of the intellectual property and pipeline despite current operational unprofitability. Alternative valuation metrics such as the price-to-sales ratio of 48.13 and an EV/EBITDA of -1.31 suggest that the stock is priced based on revenue multiples and cash flow potential rather than current earnings power, as the negative EV/EBITDA highlights the current inability to generate earnings before interest, taxes, depreciation, and amortization. The 52-week high is $7.54 and the 52-week low is $4.00, meaning the current trading price sits within a range that reflects significant volatility and sensitivity to clinical trial updates or regulatory news. The beta value is 1.21, which signifies that the stock price is 21% more volatile than the broader market, exposing investors to higher fluctuations in value compared to large-cap pharmaceutical stocks.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are listed as N/A, indicating that the company is not yet in a phase of consistent historical growth reporting required to calculate these standard metrics, which is common for companies transitioning from research phases to commercialization. Because the growth rates are not calculable, it is impossible to determine if earnings are growing faster or slower than revenue, but the current financial structure implies that earnings are heavily dependent on non-operating factors rather than operational expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available earnings and cash flows are theoretically available for reinvestment into growth initiatives, clinical trials, and research rather than distribution to shareholders. The overall growth and income profile for Abeona Therapeutics is characterized by a lack of current income distribution and undefined historical growth rates, relying entirely on the successful commercialization of its gene therapy pipeline to drive future valuation appreciation.